Antibacterial Treatments that don’t Rely on Antibiotics Winding their way through Clinical Development

07.03.2019 05:19:04 - Therapeutics that work as Monotherapies or in Combination with Existing Drugs According to Greystone Research Associates

( - (Amherst, NH) – As bacteria grow resistant to conventional antibiotics, alternatives are being investigated, including antibodies, probiotics, bacteriophages, and antimicrobial peptides. The quest to replace the current generation of antibiotics is complicated by the methods that bacteria have acquired to evade attempts to destroy them – methods often referred to a virulence factors.

A microorganism can possess a wide array of


virulence factors. They may only express these virulence factors when in the presence of certain other microorganisms, or in a particular environment, such as a highly inflamed one. The virulence factor database (VFDB) is an integrated and comprehensive online resource for curating information about virulence factors of bacterial pathogens. Since its inception in 2004, VFDB has been dedicated to providing up-to-date knowledge of VFs from various medically significant bacterial pathogens.

A number of substance classes are being explored to identify those that will successfully treat bacterial infections.The specificity of antibodies, and the inability of bacteria to develop resistance against them, make antibodies attractive, albeit expensive, alternative therapeutic agents. Bacteriophages have been used for therapy in some parts of the world.

Antimicrobial peptides have long been considered as potential replacements for antibiotics but with limited success. Synthetic peptides and synthetic Antibiotic membrane-active agents might herald a shift. Phages are very selective in targeting bacteria: often they are specific at the strain level. This gives the use of phages for therapy two advantages: it does not affect mammalian cells and it does not create dysbiosis because the commensal bacteria are not targeted either. Taken together this will diminish the likelihood of adverse effects.

Phage lysins are enzymes used by bacteriophages to destroy the cell wall of a target bacterium and are potential replacements for antibiotics because of their direct antibacterial action, and as adjuncts because they act to reduce bacterial burden, weaken biofilms, or both. Wild-type bacteriophages that infect and kill bacteria have the potential to replace antibiotics for some indications. Bacteriophage could be used in small doses because they replicate when their host bacterium is present. During treatment of an infection they might also evolve to infect the strains causing the disease. This replication and evolution makes them unique in pharmaceutical product development.

These developments are detailed in a new and comprehensive report researched and written by Greystone Research Associates. The report – The Global Market for Non-antibiotic Bacterial Therapeutics - analyzes products and candidates in numerous drug classes that have demonstrated efficacy in treating resistant strains of bacteria. The report allows readers to evaluate the current status of treatments designed to ease the burden of decreasingly effective treatments and address the antibiotic resistance problem. It includes analysis of treatment grouping by developer, indication, and drug class, forecasts and profiles.

More information is available at

About Greystone

Greystone Research Associates is a medical technology consulting firm focused on the areas of medical market strategy, product commercialization, venture development, and market research. We assist medical and healthcare market participants in achieving their business objectives through the creation of detailed development strategies, product commercialization programs, and comprehensive market and technology research and analysis. Our market research publications are designed, researched and written to provide timely and insightful information and data on focused market segments, with the aim of providing market participants with the essential knowledge to refine and execute their marketing plans and financial targets.


Mark Smith
Voice: 603-595-4340

Source: Greystone Research Associates

Press Information:
Greystone Research Associates

98 Route 101A
Amherst, NH 03031 USA

Contact Person:
Mark Smith
Communications Director
Phone: 603-595-4340
eMail: eMail



Disclaimer: If you have any questions regarding information in this article please contact the author. Please do not contact We are not able to assist you. disclaims content contained in this article. is not authorized to give any information about content and not responsible for content posted by third party.
refer this article
Print This Article
Terms Of Use Privacy About Contact Us